DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.
Article
Google Scholar
Yuan LJ, Li JD, Zhang L, Wang JH, Wan T, Zhou Y, Tu H, Yun JP, Luo RZ, Jia WH, Zheng M. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 2014;5:e1247.
Article
CAS
Google Scholar
Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010;8:1175–87.
Article
CAS
Google Scholar
Peer D. Precision medicine--delivering the goods. Cancer Lett. 2014;352:2–3.
Article
CAS
Google Scholar
Abramovitz M, Krie A, Dey N, De P, Williams C, Leyland-Jones B. Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Curr Opin Oncol. 2016;28(6):461–8.
Article
CAS
Google Scholar
Burgess JT, Bolderson E, Saunus JM, Zhang SD, Reid LE, McNicol AM, Lakhani SR, Cuff K, Richard K, Richard DJ, O'Byrne KJ. SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. Oncotarget. 2016;7(45):72807–18.
Article
Google Scholar
Leto G, Incorvaia L, Flandina C, Ancona C, Fulfaro F, Crescimanno M, Sepporta MV, Badalamenti G. Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast CancerProgression: a Preliminary Report. Cancer Investig. 2016:1–9. PMID: 27636861
Lei B, Zhang XY, Zhou JP, Mu GN, Li YW, Zhang YX, Pang D. Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker. Tumour Biol. 2016;37(11):14757–64.
Article
CAS
Google Scholar
Friese A, Faesen AC, Huis i’VPJ, Fischböck J, Prumbaum D, Petrovic A, Raunser S, Herzog F, Musacchio A. Molecular requirements for the inter-subunit interaction and kinetochore recruitment of SKAP and Astrin. Nat Commun. 2016;7:11407.
Article
CAS
Google Scholar
Zhang H, Li S, Yang X, Qiao B, Zhang Z, Xu Y. miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 2016;35:60.
Article
CAS
Google Scholar
Välk K, Vooder T, Kolde R, Reintam MA, Petzold C, Vilo J, Metspalu A. Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology. 2010;79:283–92.
Article
Google Scholar
Thedieck K, Holzwarth B, Prentzell MT, Boehlke C, Kläsener K, Ruf S, Sonntag AG, Maerz L, Grellscheid SN, Kremmer E, Nitschke R, Kuehn EW, Jonker JW, Groen AK, Reth M, Hall MN, Baumeister R. Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells. Cell. 2013;154:859–74.
Article
CAS
Google Scholar
Abdel-Fatah TM, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SY. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 2016;17:1004–18.
Article
CAS
Google Scholar
Buechler S. Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer. 2009;9:243.
Article
Google Scholar
The landscape of candidate driver genes differs between male and female breast cancer. PloS One. 2013:e78299. PMID:24194916.
Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
Article
Google Scholar
Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33.
Article
Google Scholar
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.
Article
CAS
Google Scholar
Almudevar A. Multiple hypothesis testing: a methodological overview. Methods Mol Biol. 2013;972:37–55.
Article
Google Scholar
Bertolino F, Cabras S, Castellanos ME, Racugno W. Unscaled Bayes factors for multiple hypothesis testing in microarray experiments. Stat Methods Med Res. 2015;24:1030–43.
Article
Google Scholar
Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013;24:2801–7.
Article
CAS
Google Scholar
Teven CM, Schmid DB, Sisco M, Ward J, Howard MA. Systemic therapy for early-stage breast cancer: what the plastic surgeon should know. Eplasty. 2017;17:e7.
PubMed
PubMed Central
Google Scholar
Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6:375–92.
Article
CAS
Google Scholar
Niwa T, Shinagawa Y, Asari Y, Suzuki K, Takanobu J, Gohno T, Yamaguchi Y, Hayashi SI. Estrogen receptor activation by tobacco smoke condensate in hormonal therapy-resistant breast cancer cells. J Steroid Biochem Mol Biol. 2016. PMID:27632897.
Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101–12.
Article
Google Scholar
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.
Article
CAS
Google Scholar
Lei L, Wang X, Wu XD, Wang Z, Chen ZH, Zheng YB, Wang XJ. Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. Am J Transl Res. 2016;8:3585–92.
CAS
PubMed
PubMed Central
Google Scholar
Salazar MD, Ratnam M, Patki M, Kisovic I, Trumbly R, Iman M, Ratnam M. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein. Breast Cancer Res. 2011;13:R18.
Article
CAS
Google Scholar
Won HS, Lee KM, Oh JE, Nam EM, Lee KE. Inhibition of β-catenin to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. PLoS One. 2016;11:e0155983.
Article
Google Scholar
Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4:197–201.
Article
CAS
Google Scholar
Thein KH, Kleylein-Sohn J, Nigg EA, Gruneberg U. Astrin is required for the maintenance of sister chromatid cohesion and centrosome integrity. J Cell Biol. 2007;178:345–54.
Article
CAS
Google Scholar
Bertucci F, Viens P, Birnbaum D. SPAG5: the ultimate marker of proliferation in early breast cancer. Lancet Oncol. 2016;17:863–5.
Article
CAS
Google Scholar
Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3:27–34.
Article
CAS
Google Scholar
Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther. 2013;12:1874–85.
Article
CAS
Google Scholar
Chiu SC, Chen JM, Wei TY, Cheng TS, Wang YH, Ku CF, Lian CH, Liu CC, Kuo YC, Yu CT. The mitosis-regulating and protein-protein interaction activities of astrin are controlled by aurora-A-induced phosphorylation. Am J Physiol Cell Physiol. 2014;307:C466–78.
Article
CAS
Google Scholar
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.
Article
Google Scholar
Williams MD, Nguyen T, Carriere PP, Tilghman SL, Williams C. Protein kinase CK2 expression predicts relapse survival in ERα dependent breast cancer, and modulates ERα expression in vitro. Int J Environ Res Public Health. 2016;13:ijerph13010036.
Article
Google Scholar
Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, Wu C, Hacohen N, Signoretti S, Liu JS, Liu XS. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016;48:725–32.
Article
CAS
Google Scholar
Katayama K, Yasuda H, Tochigi Y, Suzuki H. The microtubule-associated protein astrin transgenesis rescues spermatogenesis and renal function in hypogonadic (hgn/hgn) rats. Andrology. 2013;1:301–7.
Article
CAS
Google Scholar
Kersten FF, van Wijk E, Hetterschijt L, Bauβ, Peters TA, Aslanyan MG, van der Zwaag B, Wolfrum U, Keunen JE, Roepman R, Kremer H. The mitotic spindle protein SPAG5/Astrin connects to the Usher protein network postmitotically. Cilia. 2012;1:2.
Article
CAS
Google Scholar
Fitzgerald CJ, Oko RJ, van der Hoorn FA. Rat Spag5 associates in somatic cells with endoplasmic reticulum and microtubules but in spermatozoa with outer dense fibers. Mol Reprod Dev. 2006;73:92–100.
Article
CAS
Google Scholar
Owsley J, Jimeno A, Diamond JR. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer. Drugs Today (Barc). 2016;52:119–29.
Article
CAS
Google Scholar